This website uses cookies to ensure you get the best experience on our website. Learn more

Johnson and Johnson COVID-19 Vaccine: Should You Take It?

x
  • Johnson & Johnson COVID-19 Vaccine: Effectiveness, Side Effects and Differences Between Vaccines

    2:45

    Dr. Dean Blumberg, Chief of Pediatric Infectious Diseases at UC Davis Children's Hospital, explains how the new Johnson and Johnson COVID-19 vaccine works and answers common questions, including why it's different from other coronavirus vaccines, how side effects compare to Pfizer and Moderna vaccines and more.

    For the latest information and resources on COVID-19, visit
    See the latest news from UC Davis Health:

    0:00 How is the Johnson & Johnson vaccine different?
    0:25 Why is it easier to distribute?
    1:00 Is it as effective as other COVID vaccines?
    1:44 Are the side effects different?
    2:01 Why is it important to have another vaccine available?

    #JohnsonandJohnson #covid19 #vaccine #coronavirus

  • x
  • Johnson and Johnson COVID-19 Vaccine: Should You Take It?

    14:42

    Should you take the Johnson and Johnson COVID-19 Vaccine? Rumor vs Reality: If you are offered the Johnson & Johnson vaccine, should you laugh in your doctor's face? Or is the Johnson & Johnson vaccine still a good one with more protection than you may realize? Rumor vs Reality, let's talk about it.

    This video is intended to be informational only. It is not a medical consultation, nor is it personalized medical advice. For medical advice, please consult your physician.

    Get your FREE Healthy Habits Guide!

    Subscribe so you’ll never miss my latest videos.


    ✔️ Instagram:
    ✔️ Facebook:


    Today, I'm going to address the Johnson & Johnson vaccine. I have been hearing all kinds of rumors versus reality on social media, on the telephone among friends, among family members, and people have been really giving the Johnson & Johnson vaccine a bad rep. But in today's video, I'm going to break it down. Rumor vs Reality: Is it something that should be laughed at? Or is it actually a good vaccine with more protection than you realize? I'm going to cover four topics in this video.


    1. COVID-19 Vaccines Compared
    I'll discuss the difference between the messenger RNA vaccines, like the Pfizer and Moderna, and the Johnson and Johnson vaccine. I'll talk about the difference in the science of the vaccine.

    2. COVID-19 Vaccination Data
    I'll talk about what percentage of protection you get from the messenger RNA vaccines versus the Johnson and johnson vaccine, and I'll discuss the implications of that data.

    3. Is It Fair To Compare?
    Is it fair to compare the mRNA vaccines with Johnson and Johnson vaccine given that the studies took place during different time periods?
    The Johnson and Johnson vaccine was tested while we had variants. Those same variants weren't around for Moderna and Pfizer vaccines. So is it fair to compare?

    4. Would I Take The Johnson and Johnson Vaccine?
    I will answer the question: What would I do?
    If I were offered the Johnson and Johnson vaccine, what would I do? I'll answer that question and I'll answer it honestly.


    I'm really curious to see what your thoughts are. So please drop down in the comments if number one, if you had any of the vaccines already, and then tell me what you would do. Would you get that Johnson & Johnson vaccine if it were the only vaccine available to you? I'm very curious to see what you think.


    If you enjoyed this Johnson and Johnson COVID-19 Vaccine video, if you found it to be helpful, then please be sure to like it and to share it with the people you care about. Also, make sure that you subscribe to my YouTube channel Dr. Frita.

    And make sure you follow me on Instagram so you can see what I'm up to in my everyday life.

    I thank you for watching. I appreciate you for watching. Meanwhile, do your best to live your healthiest, happiest life. I'm Dr. Frita.

    #johnsonandjohnsonvaccine #drfrita #covid19vaccine

    ⭐⭐ OTHER VIDEOS YOU MIGHT ALSO LIKE ⭐⭐
    ✅ What Is Coronavirus COVID-19? The Symptoms You Should Know!
    ✅ The Truth About Vaccines Revealed!
    ✅ How To Recognize The Signs Of Coronavirus

  • x
  • Johnson & Johnson COVID-19 Vaccine: Effectiveness and Differences Between Vaccines

    6:27

    Kemi Olatunji, Pharm.D , Director of Pharmacy Services at Riverside Regional Medical Center, explains how the new Johnson and Johnson COVID-19 vaccine works and answers common questions, including why it's different from other coronavirus vaccines, how side effects compare to Pfizer and Moderna vaccines and more.

    For the latest information and resources on COVID-19, visit riversideonline.com/covid_19

  • Mayo Clinic Insights: What you should know about the Johnson & Johnson COVID-19 vaccine

    3:16

    Mayo Clinic Insights: Dr. Swift discusses what you need to know about the new Johnson & Johnson COVID-19 vaccine. For more up to date information about COVID-19, visit

  • x
  • What You Need to Know About the Johnson & Johnson Vaccine

    2:41

    Aisha Langford, MPH, PhD, assistant professor in NYU Langone’s Department of Population Health, explains how the Johnson & Johnson vaccine works and the ways in which it is as effective as the Pfizer and Moderna vaccines.

  • Coronavirus Update 121: Johnson and Johnson Vaccine - Efficacy and Safety vs. Pfizer & Moderna

    11:49

    Professor Roger Seheult, MD explains the Johnson and Johnson / Janssen Pharmaceuticals vaccine candidate for COVID 19. Dr. Seheult illustrates how the Johnson & Johnson adenovirus vaccine works, the efficacy/safety (based on preliminary data), and how the vaccine compares to the Moderna vaccine and the Pfizer BioNTech vaccine. (This video was recorded on February 4, 2021).

    Roger Seheult, MD is the co-founder and lead professor at
    He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.

    Interviewer: Kyle Allred, Physician Assistant, Producer / Co-Founder of MedCram.com

    LINKS / REFERENCES:

    A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (NIH) |

    Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial (Johnson & Johnson) |

    J&J one-dose Covid vaccine is 66% effective, a weapon but not a knockout punch (STAT) |

    One-shot COVID-19 vaccine is effective against severe disease (ScienceNews) |

    UK COVID Symptom Study |

    Doctor Explains The PREVENTION & TREATMENT For The Coronavirus | Roger Seheult & Lewis Howes (Lewis Howes YouTube Channel) |


    THE MEDCRAM WEBSITE:

    Visit us for videos on over 60 medical topics and CME / CEs for medical professionals:


    SUBSCRIBE TO THE MEDCRAM YOUTUBE CHANNEL:


    Get notified of new videos by hitting the bell icon:


    RECENT PREVIOUS COVID-19 UPDATES:

    Please visit MedCram.com for the full series:
    - Coronavirus Update 120: Anticoagulants (Blood Thinners) Improve Hospital Outcomes (Full Dose)
    - Coronavirus Update 119: Pfizer BioNTech COVID Vaccine (Clinical Considerations)
    - Vitamin D and COVID 19: The Evidence for Prevention and Treatment of Coronavirus (SARS CoV 2)
    - Coronavirus Update 118: AstraZeneca DNA COVID 19 Vaccine Explained (vs. Pfizer / BioNTech, Moderna)
    - Coronavirus Update 117: Moderna vs. Pfizer COVID 19 Vaccine (mRNA vaccines)
    - Coronavirus Update 116: Pfizer COVID 19 Vaccine Explained (Biontech)
    - Coronavirus Update 115: Convalescent Plasma vs Monoclonal Antibodies for COVID 19 Treatment
    - Coronavirus Update 114: COVID 19 Death Rate Drops; NAC (N acetylcysteine) Data
    - Coronavirus Update 113: Remdesivir May Not Work for COVID 19
    - Coronavirus Update 112: Linoleic Acid; Vaccines; UK COVID 19 Data
    - Coronavirus Update 111: Masks; New Vitamin D Data and COVID 19; NAC
    - Coronavirus Pandemic Update 110: Trump's Risk Factors and COVID-19 Prognosis; Interferon
    - Coronavirus Pandemic Update 109: New Data From Europe As COVID 19 Infections Rise
    - Coronavirus Pandemic Update 108: High Risk COVID 19 Behaviors; Cases Rise in Europe
    - Coronavirus Pandemic Update 107: Monoclonal Antibodies for COVID 19 Treatment and Prevention?

    All coronavirus updates are at ad-free MedCram.com (including this video on the Johnson and Johnson Vaccine).
    We offer over 60 medical topics (ECG Interpretation, DKA, influenza, measles, mechanical ventilation, etc.) on our website.


    MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS:

    MedCram offers group discounts for students and a variety of medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested.


    MEDIA CONTACT:

    Media Contact: customers@medcram.com
    Media contact info:

    Video Produced by Kyle Allred

    FOLLOW US ON SOCIAL MEDIA:






    DISCLAIMER:

    MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor.
    #COVID19 #SARSCoV2 #Coronavirus

  • x
  • Johnson & Johnson: Covid vaccine booster increases protection to 94%

    5:14

    CNBC's Meg Tirrell reports on Johnson & Johnson's coronavirus vaccine and the study results behind a second dose of its Covid vaccine. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Johnson & Johnson said Tuesday its Covid-19 booster shot is 94% effective when administered two months after the first dose in the United States. It also said the booster increases antibody levels by four to six times compared with one shot alone.

    A J&J booster dose given six months out from the first shot appears to be potentially even more protective against Covid, the company said, generating antibodies twelvefold higher four weeks after the boost, regardless of age.

    When given as a booster, the vaccine remained well tolerated, with side effects generally consistent with those seen after the initial dose, according to J&J.

    “We now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly,” J&J chief scientific officer Dr. Paul Stoffels said in a statement.

    The new data, provided in a press release, helps J&J make a case to the Food and Drug Administration to authorize a booster shot to some 14.8 million Americans who have received the company’s single-dose vaccine.

    The Biden administration announced plans last month to roll out booster shots for people who received the Moderna and Pfizer vaccines. An FDA advisory committee on Friday unanimously recommended Pfizer booster shots to people age 65 and older and other vulnerable Americans. A final decision from the agency is expected any day now.

    U.S. health officials said they needed more data on the J&J vaccine before they can recommend boosters of those shots.

    The 94% efficacy rate for the J&J booster shot is for the U.S., the company said. Globally, a booster shot given about two months after the first dose is 75% effective against symptomatic infection, according to the company. It also demonstrated 100% effectiveness against severe and critical disease, it said.

    The company also released data from a real-world study that found a single dose of its vaccine provided strong and long-lasting protection against Covid-related hospitalizations, demonstrating 81% effectiveness after several months.

    The new data on a single dose will help the “critical” need “to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19 and rapidly emerging variants,” the company said.

    “A single-shot COVID-19 vaccine that is easy to use, distribute and administer that provides strong and long-lasting protection is crucial to vaccinating the global population,” Stoffels said.
    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Comparing Johnson & Johnson Janssen Covid-19 Vaccine to Pfizer and Moderna

    2:19

    MCW associate professor Dr. Ben Weston shares his knowledge on the benefits, development technology, and the safety and efficacy of the Johnson & Johnson/Janssen COVID-19 vaccine.

    Find more information and resources regarding COVID-19 vaccines here:

    To read up-to-date and trustworthy news on the COVID-19 pandemic, visit:

    0:00 – Johnson & Johnson/Janssen Vaccine Overview and Benefits

    0:37 – Johnson & Johnson/Janssen Vaccine Development Technology

    1:23 – Johnson & Johnson/Janssen Vaccine Safety

  • Infectious Disease Doctor Calls J&J COVID-19 Vaccine “A Game Changer”

    2:50

    #uvahealth #covidvaccine
    UVA Critical Care and Infectious Disease physician, Taison Bell, says he was excited about the availability of the one-dose COVID-19 vaccine from J&J. He explains how the vaccine works and addresses concerns that people may have about the vaccine’s efficacy numbers.

    Find out more about the vaccine at:

    Transcript

    TAISON BELL, MD: My name is Taison Bell. I'm a critical care and infectious disease physician at the University of Virginia.

    I was personally excited to see the Johnson & Johnson vaccine news, and then trial that came out and I expected it to be authorized by the FDA. It has a couple of advantages. So the first one is that it uses a slightly different platform. So instead of the messenger RNA that Moderna and Pfizer uses, this one uses a viral vector and adenovirus. And that's just a virus that causes the common cold, but it's modified so that it doesn't actually cause you to get sick. What it does do is allows a piece of DNA, so in opposed to RNA. It's a different vehicle, but the destination is the same.

    It’s teaching your body how to make the spike protein so that your body can make antibodies to it. And then later, if you get exposed to the coronavirus, you can rally the troops, get it out of there and prevent you from getting sick. So it works. The end game is the exact same.

    Now what I've gotten a lot of questions about is, well, what do I make of these different efficacy numbers? So, the 66% efficacy versus the 94-95%. Now you could sit back, and say, if I got the Johnson & Johnson, why would I want to take that? If I've got the Pfizer, Moderna, that I could just wait a little bit longer for? Now, this is what I want to talk about. You know, what does efficacy mean?

    If we dig down deeper into that data for Johnson & Johnson, and we think, you know, what are the things that we care about. People going to the hospital for COVID-19 with severe disease, people dying from COVID-19 from severe disease. They actually stack up pretty well against each other. So the Johnson & Johnson vaccine, for the 28 day period, before it takes for the vaccine to take full effect, from that point on, there were no people who went to the hospital with COVID-19. Absolutely zero. People who died from COVID-19, absolutely zero.

    So that 66% efficacy number is a little misleading because what this also is, is a life-saving vaccine. Now to put this in context, our flu vaccine is between 40 to 60% of efficacy. I take the flu shot every year, and it's something that we use as something to protect us from another deadly pandemic that happens on a global scale every single year. The Johnson & Johnson vaccine actually has higher efficacy than the influenza vaccine. And then when you combine that with the fact that if you look at people who've had the most severe illness and see that, you know, it really protects you against that with a one-dose regimen, that's easy to distribute, much easier to distribute. I think it's a game changer and personally for myself or my family members, if I had access to either one of them, that's the one that's going in my arm as quickly as possible, because I want the thing that's going to protect me from having a severe disease, from dying of COVID-19. And all three of these vaccines will do that.

  • x
  • Mayo Clinic Insights: How the the Johnson & Johnson COVID-19 vaccine works

    4:01

    Mayo Clinic Insights: Dr. Swift discusses what an adenovirus is and how the Johnson & Johnson COVID-19 vaccine works. For more up to date information about COVID-19, visit

  • New Data Released On Effectiveness Of Johnson & Johnson Vaccine

    2:45

    After Monday’s potentially game-changing announcement from Pfizer on its vaccine for kids 5 to 11, new data is just out about the effectiveness of the Johnson & Johnson vaccine and how it improves with a booster shot. NBC’s Stephanie Gosk reports for TODAY.

    » Watch TODAY All Day:
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    New Data Released On Effectiveness Of Johnson & Johnson Vaccine

  • Johnson & Johnson COVID-19 vaccine new data

    2:31

    About 12 million Americans received the J&J vaccine and new data shows it holds up against the new delta variant.

  • Controversy surrounding additional dose for J&J COVID-19 vaccine recipients

    2:44

    Dr. Jen Ashton has the latest news on a supplemental COVID-19 vaccine dose being offered for those who received the Johnson & Johnson shot.

  • CDC raises new concerns over Johnson & Johnson vaccine

    1:28

    CNBC's Meg Tirrell reports on CDC concerns over a neurological disorder associated with the Johnson & Johnson vaccine, and whether Covid-19 booster shots will be needed. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    The Food and Drug Administration is expected to announce a new warning for Johnson & Johnson’s Covid-19 vaccine, saying the shot has been linked to a serious, but rare, autoimmune disorder, The Washington Post reported Monday, citing four unnamed sources.

    About 100 preliminary reports of Guillain-Barre syndrome have been detected after 12.8 million doses of the J&J vaccine were administered, the Centers for Disease Control and Prevention said in a statement to NBC News. Guillain-Barre is a rare neurological disorder in which the body’s immune system mistakenly attacks part of the nervous system.

    It is estimated to affect about one person in 100,000 each year, and most people eventually recover from the disorder, according to the National Institute of Neurological Disorders and Stroke.

    The cases reported after receiving the J&J shot largely occurred about two weeks after vaccination and mostly in males, many aged 50 years and older, according to the CDC. Available data do not show a similar pattern with Pfizer’s or Moderna’s vaccine, the agency said.

    U.S. regulators are expected to emphasize that the J&J vaccine is safe and that its benefits clearly outweigh the potential risks, the Post reported, citing people familiar with the situation.

    The FDA did not immediately respond to CNBC’s request for comment.

    “Reports of GBS after receipt of the J&J/Janssen COVID-19 Vaccine in the Vaccine Adverse Event Reporting System (VAERS) are rare, but do likely indicate a small possible risk of this side effect following this vaccine,” the CDC said in the statement to NBC News.

    In a statement Monday, J&J said it has been in discussions with the FDA and other regulators about the disorder.

    “The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree,” the company said. “We strongly support raising awareness of the signs and symptoms of rare events to ensure they can be quickly identified and effectively treated.”

    The anticipated new warning is just the latest setback for J&J, which has suffered from production problems of its vaccine as well as public concerns about a rare, potentially life-threatening, blood clotting disorder linked to its shots.

    After its authorization in late February, the vaccine was touted as a blessing since it could be stored at refrigerator temperatures for months and takes just one dose — unlike Pfizer’s and Moderna’s, which require more complicated transportation methods and are two doses.

    More than 12 million of the J&J shots have been administered in the U.S., according to data compiled by the CDC.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Virologist who helped develop Johnson and Johnson COVID-19 vaccine on mixing doses

    4:41

    The Centers for Disease Control and Prevention will review the Food and Drug Administrations's decision to approve booster shots for the Moderna and Johnson and Johnson vaccines, which would allow more than 15 million Americans to get a booster shot. Dr. Dan Barouch, a physician at Beth Israel Deaconess Medical Center in Boston and director at the Center For Virology and Vaccine Research who helped develop the Johnson & Johnson COVID-19 vaccine, joins CBSN to discuss mixing and matching doses.

    CBSN is CBS News’ 24/7 digital streaming news service featuring live, anchored coverage available for free across all platforms. Launched in November 2014, the service is a premier destination for breaking news and original storytelling from the deep bench of CBS News correspondents and reporters. CBSN features the top stories of the day as well as deep dives into key issues facing the nation and the world. CBSN has also expanded to launch local news streaming services in major markets across the country. CBSN is currently available on CBSNews.com and the CBS News app across more than 20 platforms, as well as the Paramount+ subscription service.

    Subscribe to the CBS News YouTube channel:
    Watch CBSN live:
    Download the CBS News app:
    Follow CBS News on Instagram:
    Like CBS News on Facebook:
    Follow CBS News on Twitter:
    Subscribe to our newsletters:
    Try Paramount+ free:

    For video licensing inquiries, contact: licensing@veritone.com

  • WATCH: How the Johnson & Johnson COVID-19 vaccine works

    1:37

    Johnson & Johnson's COVID-19 vaccine was the third to be authorized in the United States, but it was the first to deliver full protection with one shot. Also different from the mRNA-based vaccines developed by Pfizer and Moderna, this one uses a viral vector -- in this case, an adenovirus -- to inoculate recipients against the coronavirus.

    On Thursday, Johnson & Johnson announced that new data from small studies suggest that its vaccine protects recipients against the more transmissible delta variant of the virus, and that overall protection lasts for at least eight months.

    Here’s a look at how it works.

    Video by Megan McGrew and Isabella Isaacs Thomas/PBS NewsHour

    Editor’s note: Johnson & Johnson is a funder for the PBS NewsHour.

    Stream your PBS favorites with the PBS app:
    Find more from PBS NewsHour at
    Subscribe to our YouTube channel:

    Follow us:
    Facebook:
    Twitter:
    Instagram:

    Subscribe:
    PBS NewsHour podcasts:
    Newsletters:

  • Pfizer, Moderna And J&J COVID-19 Vaccines: What Are The Differences? | TODAY

    4:15

    A third coronavirus vaccine from Johnson & Johnson could soon be on the way. What is the difference between the three coronavirus shots from Johnson & Johnson, Pfizer and Moderna? NBC senior medical correspondent Dr. John Torres joins Weekend TODAY to weigh in, and reminds reviewers that “any shot you can get at this point is the best shot for you to get.”
    » Watch TODAY All Day:
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    #Coronavirus #Vaccine #TODAY

    Pfizer, Moderna And J&J COVID-19 Vaccines: What Are The Differences? | TODAY

  • Coronavirus: Does the Johnson and Johnson Vaccine Need a Booster for Delta Variant?

    2:12

    The delta variant is not only raising concerns for the unvaccinated, but also for people who got the Johnson and Johnson vaccine. Damian Trujillo reports.

    Stay connected:
    Follow us on Twitter:
    Like us on Facebook:
    Follow us on Instagram:
    Add us on Snapchat @NBCBayArea

    Catch up on all the day's news:

    Download our app:
    On iOS:
    On Android:

  • J&J says data supports boosting single-shot Covid-19 vaccine

    4:06

    CNBC's Meg Tirrell reports on new research from Johnson & Johnson supporting a booster to its Covid vaccine. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Johnson & Johnson said Wednesday a booster shot of its Covid-19 vaccine generated a promising immune response in early stage clinical trials – though the information provided by the company in a press release was light on some details.

    J&J’s vaccine requires only one dose and recipients are considered fully vaccinated two weeks after receiving the shot. The company said Wednesday that J&J recipients who received a booster dose of the shot generated virus-fighting antibodies “nine-fold higher” than those seen four weeks after a single dose.

    Increases in antibody responses were observed in vaccine trial participants between ages 18 and 55, the company said, and in those 65 years and older who received a lower dosage of the booster shot.

    The results are based on two Phase 1/2 studies, according to the company.

    “We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months,” Dr. Mathai Mammen, head of research and development at J&J’s Janssen vaccine arm, said in a statement.

    “With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” he added.

    While the new data is promising, the company’s press release made no mention of the booster shots’ potential impact on the coronavirus delta variant or on safety.

    When asked about data on delta, J&J referred CNBC to a report in July that showed a single dose of the vaccine generated a promising immune response to the variant.

    It also raises questions about why J&J recipients need booster shots – especially after the July report showed that a single shot of its vaccine provides immunity that lasts at least eight months and appears to deliver adequate protection against the fast-spreading delta variant.

    To be sure, the Centers for Disease Control and Prevention has said J&J recipients will probably need a booster dose but added it doesn’t have enough data right now to support a formal recommendation.

    The company said Wednesday it is engaging with the Food and Drug Administration and other health authorities regarding booster shots.

    The new data comes less than a week after J&J announced that Alex Gorsky was stepping down as CEO. Gorsky, 61, who was chairman and CEO for nine years, will become executive chairman.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Johnson & Johnson COVID-19 Vaccine

    16:48

    Dr. Dana Mazo discusses the Johnson & Johnson COVID-19 vaccine.

  • x
  • If You Received the J&J Vaccine, What Symptoms Should You Look Out For? | TODAY

    3:37

    NBC News medical correspondent Dr. John Torres joins Weekend TODAY to answer viewer questions surround the Pfizer, Moderna and Johnson & Johnson COVID-19 vaccines. He notes that the reports of blood clots associated with the J&J shot are one in a million, and all three vaccines are “very safe and very effective.”» Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:

    If You Received the J&J Vaccine, What Symptoms Should You Look Out For? | TODAY

  • FDA panel backs another shot for some Johnson & Johnson COVID-19 vaccine recipients

    10:10

    An FDA advisory panel on Friday recommended a second booster dose for Johnson & Johnson's single-shot vaccine. Dr. Celine Gounder, an infectious disease specialist and epidemiologist at New York University's Grossman School of Medicine, and Dr. Ashish Jha, the dean of Brown University's School of Public Health, join William Brangham to discuss.

    Stream your PBS favorites with the PBS app: 
    Find more from PBS NewsHour at 
    Subscribe to our YouTube channel: 

    Follow us:
    Facebook: 
    Twitter: 
    Instagram: 

    Subscribe:
    PBS NewsHour podcasts: 
    Newsletters: 

  • How long does immunity last from the Johnson & Johnson COVID-19 vaccine?

    2:03

    Answers to your latest coronavirus questions from Dr. Jen Ashton.

  • Johnson and Johnson COVID Vaccine from Janssen

    5:58

    Johnson and Johnson COVID Vaccine from Janssen

    The NEW COVID Vaccine from Johnson and Johnson has arrived. It has 2 BIG advantages compared to the mRNA vaccines. One, it's a single dose. Two, it does not require super-cold temperatures. This will make it way easier to mass vaccinate.

    The study was called the ENSEMBLE Trial, a randomized, double-blind, placebo-controlled phase 3 study, meaning that thousands of patients are enrolled and assess the vaccine's safety and efficacy. Unlike the Pfizer/BioNTech and Moderna vaccines, mRNA vaccines, the Johnson and Johnson vaccine is a recombinant vector. In this case, it takes another virus, an adenovirus, to modify that virus to cause infection in the body. However, that virus can still serve as a delivery messenger to deliver the genetic code for some SARS-CoV-2 viruses. Specifically, the genetic code that codes for the spike protein of the virus. One of the enormous advantages of this Johnson and Johnson vaccine is that it is a single-dose vaccine. The other significant advantage of this Johnson and Johnson vaccine is that it can remain stable for two years at -20°C (-4°F), at least three months of which can be at temperatures of 2-8°C (36°F–46°F).

    Why is this significant?
    Because that means, unlike the mRNA vaccines, regular refrigeration will suffice for mass distribution.

    But how effective is this Johnson and Johnson vaccine?
    The ENSEMBLE trial enrolled over 43,000 participants ages 18 years and older from the United States, Latin America, and South Africa. About 1% of patients enrolled in the study developed covid. It was 66% effective at preventing moderate and severe Covid by day 28 after vaccination among all participants, including those who lived in regions with the new emerging viral variant such as the P1 variant in Brazil and B.1.351 variant in South Africa. Protection against SARS-CoV-2 was most significant in the United States at 72% and worst in South Africa at 57%. About 95% of those in the trial who developed covid in South Africa were found to have been infected with the B.1.351 variant.

    That B.1.351 variant has been found to have some resistance to antibodies generated due to previous infections and other vaccines. Within the B.1.351 variant, the E484K mutation has appeared sporadically in multiple samples for months. Still, until recently, it didn't appear to offer the virus an advantage in populations with no preexisting immunity. But it's a different story in places like South Africa, where many people had been previously infected. In South Africa, there has been a very high reinfection rate to the point where the previous infection does not seem to protect you.

    But how protective is the Johnson and Johnson vaccine against SEVERE disease?
    It was 85% effective in all regions by day 28, and there was no severe covid after day 49.

    Does this mean the Johnson and Johnson vaccine is 100% effective at preventing severe covid by day 49?
    We will only know for sure with time and once the entire data from the study becomes available. It’s also worth noting that no one who received the Johnson and Johnson vaccine was hospitalized with covid or died with 28 days of getting this covid vaccine.
    Preventing severe disease in a high percentage of people will significantly alleviate this virus's devastation.

    How safe is the Johnson and Johnson vaccine?
    Serious adverse events, meaning side effects, were rare, with more participants in the placebo group reported adverse events than the vaccine group. This implies that some of the adverse events reported by patients in the placebo arm may have contracting actual COVID disease. The overall rates of fever were 9%. The percentage of people who developed high fevers, meaning Grade 3 fevers, defined as greater than 39°C or 102.1°F) 0.2%.

    So, Johnson and Johnson vaccine will soon be filing for Emergency Use Authorization in the United States. This comes in the nick of time because we have to vaccinate as quickly as possible before the new variants become the dominant strain. Because if that happens, the consequences could entail ineffective antibody protection, which means we would take a giant step backward to get this pandemic under control.

    Doctor Mike Hansen, MD
    Internal Medicine | Pulmonary Disease | Critical Care Medicine
    Doctor Hansen's Courses:
    Contact and Social Media Links:

    #vaccine​ #covid

  • Comparing Johnson & Johnson Vaccine to Pfizer And Moderna | NBC News NOW

    3:27

    NBC News’ Erika Edwards compares and contrasts the Johnson & Johnson vaccine to those of Pfizer and Moderna, addressing concerns about efficacy rate and ingredients.
    » Subscribe to NBC News:
    » Watch more NBC video:

    NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.

    Connect with NBC News Online!
    NBC News App:
    Breaking News Alerts:
    Visit NBCNews.Com:
    Find NBC News on Facebook:
    Follow NBC News on Twitter:
    Follow NBC News on Instagram:

    #Vaccine #FactCheck #NBCNews

    Johnson & Johnson Vaccine Fact-Check: Efficacy, Contents And Side Effects | NBC News NOW

  • Which COVID Vaccine Booster is Best? Pfizer vs. Moderna vs. J. Johnson

    16:01

    Roger Seheult, MD of MedCram explains COVID 19 booster data on Moderna, Pfizer-BioNTech, and Johnson & Johnson and the efficacy of each coronavirus booster vs. full vaccination.

    (This video was recorded on October 27, 2021)


    TOPICS IN THIS VIDEO INCLUDE:

    00:00 Which COVID-19 booster should I take?
    00:15 Pre-print study looking at outcomes for original vaccines and randomized booster combinations in the United States
    01:53 Side effects for various boosters given to patients with either J&J, Moderna, Pfizer original vaccines
    05:46 Preliminary booster efficacy data: how well do IgG bind to SARS-CoV-2 spike proteins?
    10:29 Preliminary data from Pfizer-BioNTech: Efficacy of a booster on top of fully vaccinated people in randomized, placebo-controlled trial


    Roger Seheult, MD is the co-founder and lead professor at
    He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.


    LINKS / REFERENCES:

    Pfizer And BioNTech Announce Phase 3 Trial Data Showing High Efficacy Of A Booster Dose Of Their COVID-19 Vaccine (Pfizer) |

    Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report (medRxiv) |

    All coronavirus updates are at MedCram.com (including more discussion on the COVID delta variant, vaccine passport, and more).


    SUBSCRIBE TO THE MEDCRAM YOUTUBE CHANNEL:


    Get notified of new videos by hitting the bell icon

    MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS:

    MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested.


    MEDIA CONTACT:

    Media Contact: customers@medcram.com
    Media contact info:

    Video Produced by Kyle Allred


    FOLLOW US ON SOCIAL MEDIA:






    DISCLAIMER:

    MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor.

    #COVID19 #SARSCoV2 #Coronavirus

  • Concerns Over Johnson & Johnson Vaccine

    1:54

    The FDA and the CDC have recommended pausing the use of Johnson & Johnson vaccine after reports of rare blood clots. What symptoms should you look for if you receive this vaccine? NBC Bay Area’s Raj Mathai talks to experts about concerns over this specific vaccine.

    Stay connected:
    Follow us on Twitter:
    Like us on Facebook:
    Follow us on Instagram:
    Add us on Snapchat @NBCBayArea

    Catch up on all the day's news:

    Download our app:
    On iOS:
    On Android:

  • Covid-19 vaccines: Moderna vs. Pfizer vs. Johnson & Johnson comparison

    8:24

    We asked Dr. Stephen Thomas, chief of Infectious Diseases at SUNY Upstate Medical University, what we need to know about the vaccines right now and what we could learn in the coming months.

    Watch the video for a deeper explanation about the three vaccines currently available in the U.S. — Moderna, Pfizer/BioNTech and Johnson & Johnson. Moderna and Pfizer are messenger RNA, or mRNA vaccines and Johnson & Johnson is a viral vector vaccine. All three are designed to protect against Covid-19.

    According to the CDC, rather than inject the body with a weakened version of the coronavirus, these vaccines teach the body to make a protein which triggers an immune response. It’s those antibodies that our bodies produce that help keep us safe when confronted with the actual virus.

    Side Effects
    The mRNA vaccines have been administered to over 80 million people in the United States and they are safe and effective, Thomas said. Thomas was the lead principal investigator for the worldwide Pfizer/BioNTech vaccine trial.

    In data from the trials, Thomas noted, “The safety profile of these vaccines are all pretty similar, most people will experience some kind of pain at the site the vaccine was injected and most people say the pain is mild to moderate.

    Dr. Thomas also mentioned these other common side effects:
    • Mild to moderate headache
    • Mild to moderate fatigue
    • 30 to 40 percent of people might have muscle aches or joint pain
    • About ten to fifteen percent of people might develop a fever

    “The good news is if it’s going to happen to you, because it doesn’t happen to everyone, it happens pretty soon after you get vaccinated and once it starts it goes away within a couple of days,” Thomas said.

    “With Pfizer and Moderna rolling out over 80 million doses of vaccine the side effects continue to be the same as the data from the trials and we aren’t seeing any new side effects or more severe side effects,” he added.

    What about the variants?
    Work is being done in laboratories with the Moderna and Pfizer vaccines, testing people’s antibodies to see if the antibodies will neutralize the variants.

    Thomas said, “They are not as good at neutralizing those variants as they are against the predominant strain in the United States which is from China. But experiments are continuing and there is some concerning data there, which is why it’s important that we vaccinate as many people as possible, because it’s a race against the variants.”

    Thomas noted that the vaccines are still working at fifty to sixty-percent efficacy against the new variants.

    “Just to put it in context, the annual flu vaccine is about forty-five percent efficacious,” he said.

    How important is the two-dose vaccine time schedule?
    Thomas said it’s important to get these vaccines as close to the schedule as possible as they were tested in the trials. If a change is unavoidable, Thomas recommends delaying the second dose rather than getting it ahead of schedule.

    What is herd immunity and when will we have it?
    Herd immunity is achieved when enough of the population has become immune to a disease (generally through vaccinations) that it makes it difficult for that disease to spread.

    That would mean even those who are not immune would be protected.

    “Right now, about fifteen percent of the country has received at least one dose of vaccine, but that’s a far cry from the 70 to 80-percent that we are going to need to achieve herd immunity,” Thomas said.

    Thomas doesn’t think it’s going to be a vaccine supply issue, but more of a willingness for people to be vaccinated. “We’re vaccinating 2 million people a day, if that were to go to 3 million, and we have 320 million people in the country, we could achieve herd immunity by late summer.”

  • Comparing Three Vaccines - Moderna, Pfizer, and Janssen

    14:49

    Please read and agree to the disclaimer before watching this video.
    . Comparing Three Vaccines - Moderna, Pfizer, and Janssen (J&J)

    Here is a comparative view of the efficacy and side effects of Moderna, Pfizer, and Johnson and Johnson vaccines as reported in their trial results in the FDA reports.

    This discussion does not include the efficacy and side effects from the vaccination campaigns.

    Buy me a coffee :-)
    Become my patron:
    Looking to support my educational work? Donate here:

    #drbeen #koolbeens #COVID ...

    Disclaimer:
    This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
    Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional. ...
    Disclaimer:
    This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
    Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

  • Why Johnson & Johnsons COVID-19 vaccine may soon come with a warning label | Just the FAQs

    1:53

    The FDA announced a new warning would be put on the J&J COVID-19 vaccine after possible linkage to a rare autoimmune disease. Here's what it means.

  • Johnson & Johnson COVID-19 Vaccine Resumes Distribution | TODAY

    2:43

    The Johnson & Johnson one-shot coronavirus vaccine is back in distribution in more than half of the U.S., but there are new signs that vaccine hesitancy is on the rise. Sam Brock reports for TODAY.

    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:

    Johnson & Johnson COVID-19 Vaccine Resumes Distribution | TODAY

  • How is Johnson & Johnson’s COVID-19 vaccine different from others?

    2:11

    Dr. Jen Ashton answers your latest coronavirus questions.

  • Dr. Fauci: Johnson & Johnson Vaccine Is ‘Nothing But Good News’ | TODAY

    7:12

    Commenting on Johnson & Johnson’s one-dose vaccine coming closer to approval like Pfizer’s and Moderna’s, Dr. Anthony Fauci tells TODAY, “to have two is fine, to have three is absolutely better … because it increases the supply of vaccines.” He urges people to get whatever vaccine they can get first: “Where a vaccine becomes available, take it.” He also comments on a new coronavirus strain in New York City and the latest research on people with “long-haul” COVID-19 symptoms.
    » Watch TODAY All Day:
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    #Coronavirus #Vaccine #TODAY

    Dr. Fauci: Johnson & Johnson Vaccine Is ‘Nothing But Good News’ | TODAY

  • What you need to know about Johnson & Johnson’s COVID-19 vaccine

    2:13

    Dr. Jen Ashton takes a closer look at the new vaccine from J&J.

  • Johnson & Johnson Covid-19 booster shots show big increase in immune response

    7:41

    Booster doses of Johnson & Johnson's one-shot coronavirus vaccine generated a big spike in antibodies, the frontline immune system defenses against infection, the company reported. People who received a booster six to eight months after their initial J&J shots saw antibodies increase nine-fold higher than 28 days after the first shot, Johnson & Johnson said.
    The data comes from two Phase 2 studies conducted in the United States and Europe. Some of the 2,000 or so people in the studies got booster doses six months after their first doses of J&J's Janssen vaccine.
    #CNN #News

  • Are there advantages to the Johnson & Johnson COVID-19 vaccine?

    2:13

    Dr. Jen Ashton answers viewers’ coronavirus questions.

  • In-Depth: New study on Johnson & Johnson vaccine efficacy

    2:52

    A new study claims that the antibodies created through the Johnson & Johnson COVID-19 vaccine may not be as strong as those created by the Pfizer and Moderna vaccines. But experts say the study is no cause to rush to conclusions about the vaccine.

  • FDA Issues Warning About J&J Covid Vaccine

    5:29

    Jul.13 -- Dr. Amesh Adalja, Johns Hopkins Center for Health Security senior scholar, discusses the warning added to Johnson & Johnson’s Covid-19 vaccine and the potential need for a third vaccine booster dose. The Johns Hopkins Bloomberg School of Public Health is supported by Michael R. Bloomberg, founder of Bloomberg LP and Bloomberg Philanthropies.

  • The COVID-19 Vaccines from Johnson & Johnson and AstraZeneca: Whats in Them and How Do They Work?

    11:20

    Learn about the composition and delivery mechanism for the new classes of COVID-19 vaccines based on adenovirus from Johnson & Johnson and AstraZeneca with Dr. Jonathan Genzen, COO of ARUP Laboratories and an Associate Professor at the University of Utah School of Medicine.

  • Johnson & Johnson COVID-19 Vaccine: WHO - Press Conference

    1:4:06

    WHO Strategic Advisory Group of Experts on Immunization (SAGE) presenting its interim recommendations on the use of Johnson & Johnson COVID-19 vaccine.

    Speakers:
    Dr Alejandro CRAVIOTO, Chair, Strategic Advisory Group of Experts (SAGE) on Immunization
    Dr Annelies WILDER-SMITH, Technical Advisor to the SAGE Secretariat, WHO
    Dr Kate O’BRIEN, Director, Department of Immunization, Vaccines and Biologicals, WHO

  • Which Does Dr. Fauci Prefer: The Pfizer, Moderna, Or Johnson & Johnson Vaccine?

    5:04

    Which Covid-19 vaccine should you take? Dr. Anthony Fauci says that you should take the one most readily available to you. Keep watching for part three of Dr. Fauci's interview with Stephen Colbert. #Colbert #DrAnthonyFauci #DrFauci

    Subscribe To The Late Show Channel:
    Watch full episodes of The Late Show:
    Like The Late Show on Facebook:
    Follow The Late Show on Twitter:
    Follow The Late Show on Instagram:


    Watch The Late Show with Stephen Colbert weeknights at 11:35 PM ET/10:35 PM CT. Only on CBS.

    Get the CBS app for iPhone & iPad! Click HERE:

    Get new episodes of shows you love across devices the next day, stream live TV, and watch full seasons of CBS fan favorites anytime, anywhere with CBS All Access. Try it free!

    ---
    The Late Show with Stephen Colbert is the premier late night talk show on CBS, airing at 11:35pm EST, streaming online via CBS All Access, and delivered to the International Space Station on a USB drive taped to a weather balloon. Every night, viewers can expect: Comedy, humor, funny moments, witty interviews, celebrities, famous people, movie stars, bits, humorous celebrities doing bits, funny celebs, big group photos of every star from Hollywood, even the reclusive ones, plus also jokes.

  • Frequently Asked COVID-19 Vaccine Questions - August 2021 Update

    14:10

    Effective vaccines against COVID-19 have been available since December 2020. With the Delta variant circulating around the world, do the vaccines still work? Is one vaccine better than another? Will I need a booster shot? Infectious disease and global health expert Carlos del Rio, MD, of Emory University and Chief Health Officer at University of Michigan Preeti Malani, MD, MSJ, answer your questions.

    0:00 Introduction
    0:06 Vaccines have only been available in the US since December 2020, so how do I know they're safe long-term?
    0:39 What is the Delta variant? And should I be worried?
    1:47 Are vaccinated people safe from the Delta variant?
    2:56 What is a breakthrough infection, and should I be worried?
    3:43 Are all breakthrough infections due to the Delta variant or is something else going on?
    4:06 Will I need a booster dose later this year or next?
    4:39 Should I avoid the Johnson & Johnson/Janssen vaccine, or the AstraZeneca vaccine? Are some vaccines better than others?
    5:56 I had COVID and have long-haul symptoms. Will vaccination help or make them worse?
    6:17 How long am I protected?
    6:39 What can I do after I'm fully vaccinated?
    7:31 Should I be vaccinated if I still need to wear a mask and physically distance afterwards?
    8:11 If over half of people are vaccinated, why do I still need to take it?
    8:51 I've had a severe reaction to a vaccine before. Is the vaccine safe for me?
    9:18 I've heard a lot about bad vaccine reactions, including deaths. What are those? And should I be concerned?
    9:49 Can I use over-the-counter painkillers to treat the side effects of vaccination?
    10:13 Vaccination during pregnancy. Do we know if the vaccine is safe for those who are pregnant or breastfeeding?
    11:07 I'm immunosuppressed. Will the vaccine still protect me?
    11:51 Is the vaccine safe for kids over age 12?
    12:29 Should I worry about my unvaccinated young children returning to school?
    13:29 Will children under the age of 12 be eligible for the COVID vaccine?

  • What’s Different About the Johnson & Johnson COVID-19 Vaccine?

    5:59

    It’s official: The Johnson & Johnson vaccine has been granted emergency use authorization by the US FDA, joining the ranks of Moderna and Pfizer. Here's why this decision could be a game-changer for vaccine distribution.
    » Subscribe to Seeker!
    » Watch more Elements!
    » Visit our shop at

    While not as high as Moderna’s and Pfizer’s 94 and 95% overall efficacy, this vaccine was found to be 85% effective against severe disease, regardless of the region or what variant it is exposed to. What’s more, it requires a single dose to work and doesn’t have specialized freezers — two attributes which could be a MASSIVE game changer for expanding access across the globe.

    Not only that, but the J&J vaccine is more durable than many of its counterparts, particularly those developed by Moderna and Pfizer.
    Also, unlike mRNA based vaccines, which are incredibly fragile and require cold storage to protect from damage, the J&J vaccine doesn’t require the same ultra-cold storage to stay intact. In fact, it can keep in a regular refrigerator for up to three months.

    So, how exactly did J&J bring this all together? Well, it all has to do with how its vaccine is formulated. Similar to the University of Oxford’s Astrazeneca vaccine and China’s CanSino vaccine, it uses a modified adenovirus as its vector: specifically, Ad26. That adenovirus is going to induce certain kinds of protective responses that will allow this little piece of COVID that we stuck into it to have a much greater effect. Once the little piece of COVID is inside the cell nucleus, its DNA code for creating a spike protein gets translated into RNA. The cell can then ‘read’ those instructions to make copies of the virus’s spike protein. These copies trigger the body’s immune response, helping it to become familiar with the virus and develop a plan of attack, should the two ever meet again.

    #COVID #COVID-19 #Coronavirus #vaccine #vaccines #JohnsonandJohnson #seeker #science #elements

    Read More:

    J&J’s single-dose COVID vaccine raises hopes for faster rollout

    US regulators have authorized Johnson & Johnson’s vaccine — which does not require a booster shot, and could simplify the logistics of mass vaccination.

    Why The Johnson & Johnson Vaccine Has Gotten A Bad Rap — And Why That's Not Fair

    First of all, I want to make the case that the J&J vaccine is not a lesser vaccine. And second is we absolutely should not be distributing these things based on socioeconomic status or any of those things.

    What are Adenovirus-Based Vaccines?

    Adenoviruses are considered excellent vectors for delivering target antigens to mammalian hosts because of their capability to induce both innate and adaptive immune responses.

    ____________________

    Elements is more than just a science show. It’s your science-loving best friend, tasked with keeping you updated and interested in all the compelling, innovative, and groundbreaking science happening all around us. Join our passionate hosts as they help break down and present fascinating science, from quarks to quantum theory and beyond.

    Seeker empowers the curious to understand the science shaping our world. We tell award-winning stories about the natural forces and groundbreaking innovations that impact our lives, our planet, and our universe.

    Visit the Seeker website

    Elements on Facebook

    Subscribe now!

    Seeker on Twitter

    Seeker on Facebook

    Seeker

  • J&J vaccine much less effective against delta variant: New study

    1:26

    An NYU lab study suggests that one dose of the Johnson & Johnson vaccine is significantly less effective against the delta variant. The study confirms that Moderna and Pfizer's covid vaccines are still effective against the delta strain. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Intensive-care unit and lung doctor Dr. Vin Gupta told CNBC that he’s already encouraging patients who received the single-shot Johnson & Johnson Covid vaccine to get a Pfizer or Moderna booster shot amid the dramatic increase in delta variant cases across the U.S.

    Gupta, a professor at the University of Washington’s Institute for Health Metrics and Evaluation, told “The News with Shepard Smith” that “AstraZeneca, when combined with a Pfizer or Moderna booster, is showing tremendous levels of protection against delta, in terms of the antibody levels that are generated in patients.”

    “I do think that those one-shot J&Jer’s should be given the opportunity, while we complete our clinical trial ... I’m already telling my patients to do it, if they can get access to it.”

    Gupta’s comments come on the heels of a new study from a lab at New York University Tuesday that raises serious questions about the effectiveness of J&J’s single-dose vaccine against the highly contagious delta variant. The NYU study is not yet peer reviewed, but found that the antibody levels in those who received the J&J shot may be low enough to be less protective.

    CNBC correspondent Meg Tirrell interviewed the lead author of the study, Dr. Ned Landau, who told her that the study suggests, “one should at least consider a second vaccination, a second shot” with the J&J vaccine, either of the same vaccine, or one from Pfizer or Moderna.

    J&J told CNBC that its own data showed the vaccine “generated strong, persistent activity against the delta variant and other highly prevalent variants.”

    The Centers for Disease Control and Prevention told CNBC that it stands by its statement earlier this month about boosters that “Americans who have been fully vaccinated do not need a booster at this time.”

    Gupta furthered the case for administering a booster shot when he told host Shepard Smith that his “definition of fully vaccinated is two doses of a vaccine.”

    Smith asked for clarification on whether Gupta considers the nearly 13 million Americans who received the J&J dose were actually fully vaccinated.

    “I think you’re protected, likely from the hospital and severe outcomes from say, the delta variant, based on what data we do have,” Gupta said. “I do not think you have the same level of protection to transmit the virus than somebody who received two doses of the vaccine like Pfizer or Moderna. I think that is pretty clear at this point.”

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Johnson & Johnson releases COVID-19 vaccine booster study

    9:37

    Johnson & Johnson says new research shows a second shot of its COVID vaccine boosts antibodies nine-fold. Meanwhile, the debate over mask and vaccine mandates is dividing Americans. CBS News national correspondent Mark Strassmann reports, then Dr. Amesh Adalja from Johns Hopkins University Bloomberg School of Public Health joins CBSN to discuss the latest research.

    CBSN is CBS News’ 24/7 digital streaming news service featuring live, anchored coverage available for free across all platforms. Launched in November 2014, the service is a premier destination for breaking news and original storytelling from the deep bench of CBS News correspondents and reporters. CBSN features the top stories of the day as well as deep dives into key issues facing the nation and the world. CBSN has also expanded to launch local news streaming services in major markets across the country. CBSN is currently available on CBSNews.com and the CBS News app across more than 20 platforms, as well as the Paramount+ subscription service.

    Subscribe to the CBS News YouTube channel:
    Watch CBSN live:
    Download the CBS News app:
    Follow CBS News on Instagram:
    Like CBS News on Facebook:
    Follow CBS News on Twitter:
    Subscribe to our newsletters:
    Try Paramount+ free:

    For video licensing inquiries, contact: licensing@veritone.com

  • Demand drops for Johnson & Johnson COVID-19 vaccine

    4:09

    Apparently fewer people are asking for Johnson & Johnson's COVID-19 vaccine even though it's a convenient, one-and-done shot. The lingering lack of confidence in J&J's product follows its 10-day suspension over a rare but serious blood clotting problem that affected mostly women. Public health experts say the vaccine's still very useful in reaching out to underserved communities.

    Don’t forget to SUBSCRIBE for daily videos:
    **More info & videos below**

    For full episodes, check out

    Let us know what you think!
    Facebook:
    Twitter:

    -----------------

    While NJ PBS does not and cannot review every submission and is not responsible for the content of your comments, NJTV reserves the right to delete, remove, move, or edit comments that it, in its sole discretion, deems abusive, defamatory, obscene, or otherwise inappropriate or unacceptable for any reason.

    -----------------

    NJ Spotlight News with Briana Vannozzi is a week-nightly news program on NJ PBS covering local New Jersey news as well as a multi-platform, local information source for New Jersey.

    Be sure to share with us your story ideas, feedback and tips about news in your neighborhood here:

    NJ Spotlight News with Briana Vannozzi airs every weeknight at 6, 7:30 and 11 p.m. ET on NJ PBS.

  • The latest on the Johnson & Johnson COVID-19 vaccine

    2:32

    Dr. Jen Ashton has what you need to know about the pause in the Johnson & Johnson vaccine distribution.

  • Johnson & Johnson Recommends Booster Shot Of Its Vaccine

    2:28

    On Wednesday morning, Johnson & Johnson announced data supporting the use of its COVID-19 vaccine as a booster shot. Meanwhile, there is a growing backlash among healthcare workers who are voicing frustrations over some Americans who are refusing to get vaccinated. NBC’s Gabe Gutierrez reports for TODAY from Tampa, Florida.

    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:

    #J&J #Vaccines #Coronavirus

  • Johnson & Johnson Is ‘Still A Safe Vaccine,’ Says Dr. John Torres | TODAY

    5:54

    NBC News medical correspondent Dr. John Torres joins the 3rd Hour of TODAY and weighs in on the CDC and FDA recommendation that the U.S. pauses distribution of the Johnson & Johnson COVID-19 vaccine. “They can’t make a direct link, but they just want to make sure that link is not there,” he says. “This is a message going out to doctors more than it is going out to the general public.” He also shares what recipients of the Johnson & Johnson vaccine should know and how long he thinks the pause will last.
    » Watch TODAY All Day:
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    #JohnsonAndJohnson #Vaccine #TodayShow

    Johnson & Johnson Is ‘Still A Safe Vaccine,’ Says Dr. John Torres | TODAY

  • FDA panel recommends Johnson & Johnson COVID vaccine booster

    3:29

    An FDA panel recommended Johnson & Johnson's COVID-19 booster shot for adults 18 and older. The panel suggested getting the booster as early as two months after the original shot. Mireya Villarreal has more.

    CBS Evening News with Norah O'Donnell delivers the latest news and original reporting, and goes beyond the headlines with context and depth. Catch the CBS Evening News every weekday night at 6:30 p.m. ET on the CBS Television Network and at 10 p.m. ET on CBSN.

    Subscribe to the ���CBS Evening News YouTube channel:
    Watch full episodes of CBS Evening News���:
    Follow CBS Evening News on Instagram:
    Like CBS Evening News on Facebook:
    Follow CBS Evening News on Twitter:
    Download the CBS News app:
    Try Paramount+ free:

    For video licensing inquiries, contact: licensing@veritone.com

Shares

x

Check Also

Menu